TNFSF10

TNFSF10 Full Name

tumor necrosis factor (ligand) superfamily, member 10

TNFSF10 Introduction

TNFSF10, also widely known as TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), has become an increasingly important therapeutic target for researchers trying to understand why certain cancers, inflammatory disorders, and degenerative diseases continue to resist conventional treatment. Encoded on chromosome 3q26, TNFSF10 belongs to the TNF ligand superfamily and is expressed as a type II transmembrane protein capable of triggering highly regulated cell death pathways. What makes TNFSF10 particularly attractive in translational medicine is its selective ability to induce apoptosis in malignant or damaged cells while sparing many normal tissues under physiological conditions. Through interaction with death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2), TNFSF10 activates caspase-dependent signaling cascades that contribute to immune surveillance and tumor suppression. However, recent studies have demonstrated that the biological activity of TNFSF10 extends far beyond classical apoptosis, revealing non-apoptotic signaling networks linked to inflammation, proliferation, immune escape, and tissue remodeling. This expanding understanding has positioned TNFSF10 at the center of next-generation oncology and immunology research, especially for investigators searching for biomarkers and druggable pathways in difficult-to-treat diseases.

One of the major challenges facing clinicians and drug developers is that TNFSF10 signaling behaves differently depending on cellular context, receptor composition, and disease stage. While early therapeutic strategies focused almost exclusively on apoptosis induction in cancer cells, newer evidence shows that TNFSF10 can also regulate NF-κB activation, autophagy, cytokine production, and survival signaling through adaptor proteins such as TRAF2 and ubiquitin-mediated modulation of caspase-8 activity. These findings help explain why some tumors develop resistance to TRAIL-based therapies despite high receptor expression. Researchers are now investigating how TNFSF10 contributes to immune microenvironment remodeling, metastatic progression, and therapy resistance in solid tumors including colorectal cancer, breast cancer, pancreatic cancer, and glioblastoma. Beyond oncology, TNFSF10 has emerged as a significant mediator of neuroinflammation and immune dysregulation. Experimental studies in Alzheimer's disease models have shown that neutralization of TRAIL signaling can reduce neuroinflammatory responses and improve cognitive impairment, highlighting its broader pathological relevance. Importantly, knockout mouse models lacking TNFSF10 or its receptors remain viable and immunologically functional, suggesting that therapeutic modulation of this pathway may offer a clinically manageable safety profile compared with other cytokine-targeted interventions.

Growing evidence also links TNFSF10 to chronic metabolic and inflammatory diseases, an area receiving substantial attention in precision medicine and biomarker discovery programs. In metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH), TNFSF10 and its receptors DR4/DR5 are frequently upregulated, particularly in hepatocytes exposed to lipid accumulation and oxidative stress. These conditions sensitize liver cells to TRAIL-mediated apoptosis, accelerating fibrosis and inflammatory liver injury. Similar pathogenic mechanisms have been reported in diabetic kidney disease, where high-glucose environments stimulate the TRAIL/DR5 axis in podocytes and promote PANoptosis, a complex inflammatory cell death program integrating apoptosis, pyroptosis, and necroptosis. Single-cell sequencing studies further support the association between elevated TNFSF10 signaling and disease progression in renal injury. Because TNFSF10 influences multiple interconnected pathways involving immunity, inflammation, and regulated cell death, it is increasingly viewed as both a therapeutic target and a disease-monitoring biomarker across oncology, hepatology, nephrology, and neurodegenerative research. For scientists and biotechnology companies developing antibody therapeutics, receptor agonists, or pathway inhibitors, TNFSF10 represents a highly promising but biologically complex target requiring carefully optimized disease-specific strategies.

Alternate Names for TNFSF10

TNFSF10; tumor necrosis factor (ligand) superfamily, member 10; TL2; APO2L; CD253; TRAIL; Apo-2L; tumor necrosis factor ligand superfamily member 10; Apo-2 ligand; TNF-related apoptosis inducing ligand TRAIL

• 1.Vitale I, et al.; Apoptotic cell death in disease-Current understanding of the NCCD 2023. Cell Death Differ. 2023, 30(5):1097-1154.
  2.Vachliotis ID, Polyzos SA. The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review. Curr Obes Rep. 2025 Aug 12;14(1):65.